{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T01:23:21Z","timestamp":1711157001843},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,21]]},"DOI":"10.7759\/cureus.56673","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T05:15:40Z","timestamp":1711084540000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Steroid Pulse Therapy Responsiveness in Myelin-Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis"],"prefix":"10.7759","author":[{"given":"Yasuyuki","family":"Takai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Yamagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayumi","family":"Iwasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Wakakura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management","volume":"13","author":"Sechi E","year":"2022","unstructured":"Sechi E, Cacciaguerra L, Chen JJ, et al.. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management. Front Neurol. 2022, 13:885218. 10.3389\/fneur.2022.885218","journal-title":"Front Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104237","article-title":"Details and outcomes of a large cohort of MOG-IgG associated optic neuritis","volume":"68","author":"Chen JJ","year":"2022","unstructured":"Chen JJ, Flanagan EP, Bhatti MT, et al.. Details and outcomes of a large cohort of MOG-IgG associated optic neuritis. Mult Scler Relat Disord. 2022, 68:104237. 10.1016\/j.msard.2022.104237","journal-title":"Mult Scler Relat Disord"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00200-9","article-title":"Diagnosis and classification of optic neuritis","volume":"21","author":"Petzold A","year":"2022","unstructured":"Petzold A, Fraser CL, Abegg M, et al.. Diagnosis and classification of optic neuritis. Lancet Neurol. 2022, 21:1120-34. 10.1016\/S1474-4422(22)00200-9","journal-title":"Lancet Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2014.03.001","article-title":"Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous system","volume":"270","author":"Tanaka M","year":"2014","unstructured":"Tanaka M, Tanaka K. Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous system. J Neuroimmunol. 2014, 270:98-9. 10.1016\/j.jneuroim.2014.03.001","journal-title":"J Neuroimmunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato DK","year":"2014","unstructured":"Sato DK, Callegaro D, Lana-Peixoto MA, et al.. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014, 82:474-81. 10.1212\/WNL.0000000000000101","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell B","year":"2023","unstructured":"Banwell B, Bennett JL, Marignier R, et al.. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023, 22:268-82. 10.1016\/S1474-4422(22)00431-8","journal-title":"Lancet Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.04.042","article-title":"Epidemiologic and clinical characteristics of optic neuritis in japan","volume":"126","author":"Ishikawa H","year":"2019","unstructured":"Ishikawa H, Kezuka T, Shikishima K, et al.. Epidemiologic and clinical characteristics of optic neuritis in japan. Ophthalmology. 2019, 126:1385-98. 10.1016\/j.ophtha.2019.04.042","journal-title":"Ophthalmology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-007-0722-2","article-title":"Visual field defects in acute optic neuritis--distribution of different types of defect pattern, assessed with threshold-related supraliminal perimetry, ensuring high spatial resolution","volume":"246","author":"Nevalainen J","year":"2008","unstructured":"Nevalainen J, Krapp E, Paetzold J, et al.. Visual field defects in acute optic neuritis--distribution of different types of defect pattern, assessed with threshold-related supraliminal perimetry, ensuring high spatial resolution. Graefes Arch Clin Exp Ophthalmol. 2008, 246:599-607. 10.1007\/s00417-007-0722-2","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.16","article-title":"Visual field profile of optic neuritis: a final follow-up report from the optic neuritis treatment trial from baseline through 15 years","volume":"128","author":"Keltner JL","year":"2010","unstructured":"Keltner JL, Johnson CA, Cello KE, Dontchev M, Gal RL, Beck RW. Visual field profile of optic neuritis: a final follow-up report from the optic neuritis treatment trial from baseline through 15 years. Arch Ophthalmol. 2010, 128:330-7. 10.1001\/archophthalmol.2010.16","journal-title":"Arch Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2016.02.004","article-title":"Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica","volume":"293","author":"Akaishi T","year":"2016","unstructured":"Akaishi T, Nakashima I, Takeshita T, et al.. Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica. J Neuroimmunol. 2016, 293:28-33. 10.1016\/j.jneuroim.2016.02.004","journal-title":"J Neuroimmunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-020-00790-9","article-title":"Intravenous immunoglobulin treatment for steroid-resistant optic neuritis: a multicenter, double-blind, randomized, controlled phase III study","volume":"65","author":"Mimura O","year":"2021","unstructured":"Mimura O, Ishikawa H, Kezuka T, et al.. Intravenous immunoglobulin treatment for steroid-resistant optic neuritis: a multicenter, double-blind, randomized, controlled phase III study. Jpn J Ophthalmol. 2021, 65:122-32. 10.1007\/s10384-020-00790-9","journal-title":"Jpn J Ophthalmol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3109\/01658107.2015.1072726","article-title":"Clinical profile of anti-myelin oligodendrocyte glycoprotein antibody seropositive cases of optic neuritis","volume":"39","author":"Matsuda R","year":"2015","unstructured":"Matsuda R, Kezuka T, Umazume A, Okunuki Y, Goto H, Tanaka K. Clinical profile of anti-myelin oligodendrocyte glycoprotein antibody seropositive cases of optic neuritis. Neuroophthalmology. 2015, 39:213-9. 10.3109\/01658107.2015.1072726","journal-title":"Neuroophthalmology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/01658107.2023.2287518","article-title":"Clinical features and prognostic factors in anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis","volume":"48","author":"Takai Y","year":"2024","unstructured":"Takai Y, Yamagami A, Iwasa M, Inoue K, Wakakura M, Takahashi T, Tanaka K. Clinical features and prognostic factors in anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis. Neuroophthalmology. 2024, 48:134-41. 10.1080\/01658107.2023.2287518","journal-title":"Neuroophthalmology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa102","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study","volume":"143","author":"Takai Y","year":"2020","unstructured":"Takai Y, Misu T, Kaneko K, et al.. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Brain. 2020, 143:1431-46. 10.1093\/brain\/awaa102","journal-title":"Brain"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231184738","article-title":"Intravenous immunoglobulin treatment for acute attacks in myelin oligodendrocyte glycoprotein antibody disease","volume":"29","author":"Lotan I","year":"2023","unstructured":"Lotan I, Chen JJ, Hacohen Y, et al.. Intravenous immunoglobulin treatment for acute attacks in myelin oligodendrocyte glycoprotein antibody disease. Mult Scler. 2023, 29:1080-9. 10.1177\/13524585231184738","journal-title":"Mult Scler"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/238672-evaluation-of-steroid-pulse-therapy-responsiveness-in-myelin-oligodendrocyte-glycoprotein-antibody-positive-optic-neuritis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T05:15:42Z","timestamp":1711084542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/238672-evaluation-of-steroid-pulse-therapy-responsiveness-in-myelin-oligodendrocyte-glycoprotein-antibody-positive-optic-neuritis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,21]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.56673","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,21]]}}}